Pilar Barrufet

Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine

Daniel Podzamczer, Elena Ferrer, Pochita Sanchez et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2006 · 137 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study)

Daniel Podzamczer, Elena Ferrer, Ezequiel Consiglio et al. · Antiviral Therapy · 2002 · 137 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

Daniel K. Nomah, Juliana Reyes‐Urueña, Yesika Díaz et al. · The Lancet HIV · 2021 · 110 citations · Full text

Public Health, Health Sciences, Infectious Diseases +17

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

Federico Pulido, Esteban Ribera, María Lagarde et al. · Clinical Infectious Diseases · 2017 · 102 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression

Estebán Martínez, J. A. Arranz, Daniel Podzamczer et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2009 · 84 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +17